Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference
Strong revenue generation in Q4 2023, including SEK 43m in Idefirix® product sales supported by growth in new markets such as U.K., Germany, and Spain Encouraging first results from first-in-human trial of HNSA-5487, Hansa’s lead candidate from the NiceR program for repeat dosing Initiation of phase 1b trial of imlifidase as pre-treatment to Sarepta’s SRP-9001 in DMD … Read more